2020-05-13T09:36:15-05:00 2019-06-30 KPMG LLP 150 W JEFFERSON SUITE 1900 DETROIT MI 48226 990 2018-07-01 954335088 Lymphoma Research Foundation % CAROL FLORES LYMP 2123492910 WALL ST PLAZA 88 PINE STREET Suite New York NY 10005 MEGHAN GUTIERREZ CEO 2123492910 2020-05-12 true Nicole Fitzmaurice P01491005 3132303340 2020-04-10 199.207.253.96 13407320201345000002 2020-05-13 P F7E791049FCEE4943A341CCA4F642AE72B60D2A0 564F1A0C6EECFEA52FD6027E033CA8250AD12734 2018 2021-01-29 14:40:06Z MEGHAN GUTIERREZ WALL ST PLAZA 88 PINE STE 240 New York NY 10005 12374668 false X www.lymphoma.org X 2001 NY THE LYMPHOMA RESEARCH FOUNDATION'S MISSION IS TO ERADICATE LYMPHOMA AND SERVE THOSE TOUCHED BY THIS DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O. 23 23 38 10000 0 7229093 7623538 2791017 3761384 118925 226544 -118198 -61895 10020837 11549571 1251239 1812125 0 0 3261065 2869837 0 0 1953258 3949008 4580164 8461312 9262126 1559525 2287445 13738328 16453671 3380869 3784012 10357459 12669659 X THE LYMPHOMA RESEARCH FOUNDATION'S (LRF) MISSION IS TO ERADICATE LYMPHOMA AND SERVE THOSE TOUCHED BY THIS DISEASE. SEE SCHEDULE O. false false 2796810 46500 EDUCATIONAL PROGRAMS AND PATIENT SERVICES: LRF PROVIDES A COMPREHENSIVE SERIES OF PROGRAMS AND SERVICES FOR THE LYMPHOMA COMMUNITY INCLUDING, BUT NOT LIMITED TO, CONTINUING MEDICAL EDUCATION, CLINICAL TRIALS INFORMATION SERVICES, DISEASE SPECIFIC PUBLICATIONS AND WEBSITES, IN-PERSON PATIENT WORKSHOPS AND EDUCATIONAL FORUMS, LYMPHOMA HELPLINE, ONLINE SERVICES, PATIENT AID GRANTS, TELECONFERENCES AND WEBCASTS/PODCASTS, WITH A VOLUNTEER COMMUNITY NETWORK. 2824342 1765625 RESEARCH: The Foundation is committed to funding the most promising lymphoma researchers who have the greatest potential to advance patient care and to supporting innovative research which will improve patient outcomes. See SCHEDULE O. 752372 COMMUNICATION AND ADVOCACY: LRF REPRESENTS THE NEEDS OF PEOPLE WITH LYMPHOMA BY SUPPORTING PUBLIC POLICIES WHICH SEEK TO INCREASE FEDERAL FUNDING FOR LYMPHOMA RESEARCH AND ENSURE ACCESS TO HIGH QUALITY CANCER CARE. THE LRF ADVOCACY PROGRAM PROVIDES VOLUNTEER ADVOCATES WITH THE RESOURCES NECESSARY TO GARNER ATTENTION AND SUPPORT FOR THOSE PUBLIC POLICIES MOST IMPORTANT TO THE LYMPHOMA COMMUNITY, THROUGH STRATEGIC COMMUNICATIONS, LRF SEEKS TO RAISE AWARENESS OF LYMPHOMA AND HAVE DISEASE INFORMATION AT THE FINGERTIPS OF MORE PEOPLE THAN EVER BEFORE. 6373524 true true false true false false false false false false true false false false false true true false false false false false false false true false false true true true false false false false false false false false true false false false false true true true false false true 49 0 true 38 true false false false false false true true false false false false false false X 23 23 true false false false false false false true true false true true true true true true true true true false true true AL AR CA FL GA HI IL KS KY MD MA MI MN MS MO NV NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X X CAROL FLORES 2123492910 WALL ST PLAZA 88 PINE STE 2400 NEW YORK NY 10005 MICHAEL AKINYELE BOARD MEMBER 1.0 0.0 X 0 0 0 ERIC COHEN BOARD MEMBER 1.0 0.0 X 0 0 0 DR MORTON COLEMAN BOARD MEMBER - CHAIR MAB 1.0 0.0 X 0 0 0 TOM CONDON BOARD MEMBER 1.0 0.0 X 0 0 0 ERROL M COOK BOARD MEMBER 1.0 0.0 X 0 0 0 KEVIN FENNESSEY BOARD MEMBER 1.0 0.0 X 0 0 0 Michael Froy Board Member (beg 11/4/18) 1.0 0.0 X 0 0 0 THOMAS E GOLDSTONE BOARD MEMBER 1.0 0.0 X 0 0 0 THOMAS HABERMANN BOARD MEMBER - SAB CHAIR 1.0 0.0 X 0 0 0 KEITH HOOGLAND BOARD MEMBER 1.0 0.0 X 0 0 0 John Leonard MD Board Member 1.0 0.0 X 0 0 0 ROBERT MCAULEY BOARD MEMBER 1.0 0.0 X 0 0 0 Kim Metcalf Board Member (beg 1/23/19) 1.0 0.0 X 0 0 0 LANCE MEYEROWICH BOARD MEMBER 1.0 0.0 X 0 0 0 JOHN A NELSON BOARD MEMBER 1.0 0.0 X 0 0 0 Leigh Olson SECRETARY 1.0 0.0 X X 0 0 0 STEVEN J PRINCE TREASURER/PAST CHAIR 2.0 0.0 X X 0 0 0 DONNA REINBOLT BOARD MEMBER 1.0 0.0 X 0 0 0 STEVEN E ROSEN BOARD MEMBER 1.0 0.0 X 0 0 0 SHERI ROSENFELD BOARD MEMBER 1.0 0.0 X 0 0 0 MICHAEL WERNER CHAIRMAN 5.0 0.0 X X 0 0 0 ROBERT WERNER BOARD MEMBER 1.0 0.0 X 0 0 0 BRUCE YABLON BOARD MEMBER 1.0 0.0 X 0 0 0 MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 35.0 0.0 X 263813 0 12913 CAROLINA FLORES SENIOR DIRECTOR OF FINANCE 35.0 0.0 X 131398 0 45810 DENNIS CHILLEMI SENIOR DIRECTOR OF DEVELOPMENT 35.0 0.0 X 152906 0 5994 PEGGY ANN TORNEY CHIEF STRATEGY,COM.&ENGA. OFF. 35.0 0.0 X 154388 0 20297 LISA WEGWEISER-VOGELL CFO & COO 35.0 0.0 X 200934 0 4170 903439 0 89184 5 true true false Marriott Business Services PO Box 402642 ATLANTA GA 30384 VENUE & CATERING 439492 BUILD CONSULTING LLC 1101 14TH STREET SUITE 830 WASHINGTON DC 20005 IT CONULTING 277093 MARRIOTT MANHATTAN BEACH 1400 PARKVIEW AVENUE MANHATTAN BEACH CA 90266 VENUE & CATERING 223764 BLACKBAUD INC 2000 DANIEL DRIVE CHARLESTON SC 29492 CONSULT/SYSTEM MAINT 172910 CPS 5 LLC 768 5TH AVENUE NEW YORK NY 10019 VENUE & CATERING 167162 5 25661 3562142 4035735 552129 7623538 EDUCATION PROGRAMS & PATIENT SERVICES 900099 3761384 3761384 3761384 227922 227922 0 0 0 0 0 550751 552129 -1378 -1378 -1378 196285 3562142 272968 -76683 -76683 0 0 0 0 0 0 OTHER ACTIVITES 14788 14788 14788 11549571 3761384 164649 1765625 1765625 46500 46500 0 0 472974 239494 90978 142502 0 1837652 934883 346607 556162 53101 28428 7774 16899 251379 112616 71423 67340 254731 129591 48046 77094 0 14297 7273 2697 4327 69325 69325 0 0 0 707490 364436 76168 266886 158213 105081 3079 50053 333089 210890 5343 116856 129932 111912 6919 11101 0 386851 197315 72154 117382 502382 422815 1532 78035 0 1432975 1338656 15953 78366 0 0 263320 133961 49666 79693 22983 11692 4335 6956 PROCESSSING FEES AND OTHER 231963 64183 16274 151506 REPAIRS AND MAINTENANCE 50209 25263 9367 15579 LICENSE AND PERMITS 9777 615 4014 5148 MISCELLANEOUS AND OTHER EXPENS 267358 122295 33690 111373 9262126 6373524 935344 1953258 1241981 1559816 10036255 13125562 300000 200000 1066035 637160 0 0 0 0 100150 0 0 0 291853 270859 781302 446995 590168 334307 111886 325967 0 0 0 0 0 0 0 0 13738328 16453671 532577 607815 2730792 2997464 117500 178733 0 0 0 0 0 0 0 0 0 0 0 0 3380869 3784012 X 3294149 4602060 7063310 8067599 0 0 10357459 12669659 13738328 16453671 X 2287445 124905 -100150 X false true X true false X 6344995 6847149 7784192 7229093 7623538 35828967 0 0 6344995 6847149 7784192 7229093 7623538 35828967 10103105 25725862 43425 57884 95465 116297 227921 540992 0 18320 5680 18492 15189 14788 72469 36442428 15623354 0.70593 0.73482 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 41353 false true 88847 130200 false Schedule C, Part II-B, Line 1 Other lobbying activities: contact with legislators, their staff, government officials, legislative bodies, and associated grassroots activities to present issues of concern related to lymphoma. 112190 25186 87004 664187 418651 245536 4925 3158 1767 334307 0 0 X 13213597 124905 1266153 1391058 11822539 -272968 -272968 11549571 10801247 1266153 272968 1539121 9262126 9262126 Schedule D, Part X, Line 2: The Foundation recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Income generated from activities unrelated to the Foundation's exempt purpose is subject to tax under Internal Revenue Code Section 511. The Foundation did not recognize any unrelated business income tax liability for the year ended June 30, 2019 or 2018. Schedule D, Part XI & XII, Line 4B & 2D Expenses related to fundraising events are reported in Part VIII, Statement of Revenue, Line 8B, together with fundraising events revenue. Team LRF 1280444 1280444 24124 23545 8360 4570 Annual Gala 1803512 1682012 121500 852 136162 8454 4 674471 599686 74785 929 58091 906 6975 3758427 3562142 196285 25905 217798 9266 19999 272968 -76683 true Tufts Medical Center Inc 800 Washington Street Box 345 Boston MA 02111 043400617 Corporation 225000 CASH Career Development Award - Hodgkin Lymphoma in the Community: Mixed Methods of Study of Practice Variation and Provider Attitudes Emory University HSRB 1760 Haygood Dr NE W200 Suite Atlanta GA 30322 580566256 501(c)(3) 225000 Cash Career Development Award - Molecular predictors in post-transplant lymphoproliferative disorder (PTLD) Washington UNiversity in St Louis 660 South Euclid Ave St Louis MO 63110 430653611 501(c)(3) 225000 Cash Career Development Award - Minimal Residual Disease in T-cell Lymphoma University of North Carolina at Chapel Hill 125 Mason Farm Road Chapel Hill NC 27599 566001393 501(c)(3) 225000 Cash Career Development Award - A new, augmented CAR-T cell targeting koppa light chains on B cell lymphomas for clinical evaluation University of Pennsylvania 3400 Civic CTR Blvd Philadelphia PA 19104 231352685 501(c)(3) 105000 Cash Fellowship Award - Development of Safe and Effective Chimeric Antigen Receptor T cells (CART) for T cell malignanices University of Pennsylvania 3400 Civic Ctr Blvd Philadelphia PA 19104 231352685 501(c)(3) 105000 Cash Fellowship Award - Determinants of response to CD19-directed CAR T cell therapy in B-cell lymphomas Icahn School of Medicine at Mount Sinai 1470 Madison Avenue New York NY 10029 136171197 Non-profit Corp 105000 Cash Fellowship - Role of FOXO1 mutations in the pathogenesis of B cell non-Hodgkin lymphomas Massachusetts General Hospital 13th Street 149 Building 3rd Floor Charlestown MA 02149 042697983 501(c)(3) 105000 Cash Fellowship Award - Chimeric antigen receptor T cells targeting CD37 antigen in T cell lymphomas The Pennsylvania State University College H138 500 University Dr Hershey PA 17033 240000370 Government 105000 Cash Fellowship Award - Contributions of the Epstein-Barr Virus Non-Protein-Coding Locus BHLF1 to Latency and Reactivation Tulane University Heatth Sciences Center 1430 Tulane Avenue sl-79 New Orleans LA 70112 720423889 Corporation 105000 Cash Fellowship Award - EBV microRNAs in Burkitt's Lymphoma Progression University of Pennsylvania 422 Currie Blvd Philadelphia PA 19104 231352685 501(c)(3) 105000 Cash Fellowship Award - NPM-ALK regulates expression of CD48 to escape immune surveillance in ALK+ALCL Beckman Research Institute of the City of Hope 1500 East Duarte Road Duarte CA 91010 953435919 501(c)(3) 105000 Cash Fellowship Award - Investigating cross-lineage activation of T-cell associated ZAP70 tyrosine kinase in B-malignancies Columbia Univeristy Medical Center 630 West 168th Street New York NY 10032 135598093 Non-profit Corp 105000 Cash Fellowship Award - Development of first-in-class histoneacetyltransferase(HAT) activators Mayo Clinic Arizona 5777 E Mayo Blvd Phoenix AZ 85254 416011702 501(c)(3) 10000 Cash Mentoring - Analytical and Clinical Validation of MCL35 in Patients with Mantle Cell Lymphoma Emory University 1365C Clifton Road NE Atlanta GA 30322 580566256 501(c)(3) 10000 Cash Mentoring - Physical Activity Intervention for Lymphoma and Myeloma Patients during Autologous Transplantation Medical University of South Carolina 39 Sabin Street Charleston SC 29425 576000722 State Agency 10000 Cash Mentoring - Oral Azacitidine (CC_486) Plus Salvage Chemotherapy in Relapsed/Refractory DLBCL University of Colorado Anschutz 1665 Aurora Court Aurora CO 80045 846000555 State Agency 10000 Cash Mentoring - Ublituximab for low tumor burden lymphoma with addition of umbralisib for suboptimal response University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd Houston TX 77030 746001118 State Agency 10000 Cash Mentoring - A Phase I/Ib Study of CC-90002, Lenalidomide and Rituximab for Patients with Relapsed B-NHL National Heart Lung and Blood Institute 10 Center Drive Bethesda MD 20814 520858115 Federal 10000 Cash Mentoring - A Phase I Study of Hu5F9-G4/Rituximab/Venetoclax in Relapsed/Refractory Indolent B-cell Malignancies Dana-Farber Cancer Institute 450 Brookline Avenue Boston MA 02215 042263040 501(c)(3) 10000 Cash Mentoring - NIvolumab-based salvage and post-autologous transplantation maintenance therapy in Hodgkin lymphoma Cleveland Clinic Foundation 9500 Euclid Avenue Cleveland OH 44195 340714553 501(c)(3) 10000 Cash Mentoring - Lenalidomide, Umbralisib and Ubituximab in Patients with Relapsed/Refractory iNHL or MCL 19 2 PATIENT AID GRANTS 465 46500 CASH Schedule I, Part I, Line 2 LRF'S Scientific Advisory Board (SAB) reviews all grant proposals and recommends to LRF's Board of Directors which grants to fund. The Board then approves the grants to be funded based upon the SAB's recommendations. Once a grant is approved and accepted by the grantee, the grantee will begin to receive installments based upon the payment schedule as dictated in the contract. The SAB and LRF's Research Department annually review each grantee's progress against deliverables and approves the continuation of grant payments. Schedule I, Part III LRF provides financial assistance to Lymphoma patients who struggle to pay for expenses related to their lymphoma treatments, such as medical bills and transportation costs. Our patient services team reviews the applications and submits them to the Chief Strategy, Communications, and Engagement Officer for payment approval. X X X true false false false false false false true false MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 248813 15000 12019 894 276726 DENNIS CHILLEMI SENIOR DIRECTOR OF DEVELOPMENT 152906 5874 120 158900 PEGGY ANN TORNEY CHIEF STRATEGY,COM.&ENGA. OFF. 154388 7644 12653 174685 CAROLINA FLORES SENIOR DIRECTOR OF FINANCE 131398 7081 38729 177208 LISA WEGWEISER-VOGELL CFO & COO 44756 156178 997 3173 205104 Schedule J, Part I line 7 Meghan Gutierrez, CEO, received discretionary, non-fixed bonus payment in calendar year 2018, which is approved by the chairman of the organization. Schedule J, Part I line 4 Lisa Wegweiser-Vogel received a severance payment of $156,178 in calendar year 2018. X 13 552129 Market Price false true false FORM 990, PART I, LINE 1 LRF IS THE NATION'S LARGEST NON-PROFIT ORGANIZATION DEVOTED TO FUNDING INNOVATIVE RESEARCH AND SERVING THE LYMPHOMA COMMUNITY THROUGH A COMPREHENSIVE SERIES OF EDUCATION PROGRAMS, OUTREACH INITIATIVES, AND PATIENT SERVICES. LRF INVESTS MILLIONS OF DOLLARS EVERY YEAR TO COMBAT LYMPHOMA AND ASSIST THOSE WHOSE LIVES HAVE BEEN AFFECTED BY A LYMPHOMA DIAGNOSIS. LRF IS SUPPORTED BY MORE THAN 10,000 VOLUNTEERS WHO CONTRIBUTE THEIR TIME AND TALENTS TO FURTHER THE LRF MISSION AND SERVE THEIR LOCAL COMMUNITIES. LRF HAS EARNED THE TRUST OF INDIVIDUALS, PRIVATE FOUNDATIONS, PUBLIC COMPANIES, AND ORGANIZATIONS THAT FUND ITS WORK BY DEMONSTRATING A HISTORY OF CAREFUL AND PROVEN FINANCIAL STEWARDSHIP. FORM 990, PART III, LINE 1 - ORGANIZATION'S MISSION LRF IS DEDICATED TO IDENTIFYNG A CURE THROUGH AN AGGRESIVELY-FUNDED RESEARCH PROGRAM AND TO HELPING MEMBERS OF THE LYMPHOMA COMMUNITY BY PROVIDING COMPREHENSIVE, DISEASE-SPECIFIC PROGRAMS AND SERVICES. LRF INVESTS MILLIONS OF DOLLARS EVERY YEAR TO COMBAT LYMPHOMA AND ASSIST THOSE WHOSE LIVES HAVE BEEN AFFECTED BY A LYMPHOMA DIAGNOSIS. LRF IS SUPPORTED BY MORE THAN 10,000 VOLUNTEERS WHO CONTRIBUTE THEIR TIME AND TALENTS TO FURTHER THE LRF MISSION AND SERVE THEIR LOCAL COMMUNITIES. LRF HAS EARNED THE TRUST OF INDIVIDUALS, PRIVATE FOUNDATIONS, PUBLIC COMPANIES, AND ORGANIZATIONS THAT FUND ITS WORK. BY DEMONSTRATING A HISTORY OF CAREFUL AND PROVEN FINANCIAL STEWARDSHIP. Form 990, Part III, line 4b RESEARCH: This work is led by the Foundation's renowned Scientific Advisory Board, comprised of 45 of the world's leading experts in lymphoma research and patient care. LRF facilitates numerous disease-specific global consortia (including programs for follicular, marginal zone, mantle cell and adolescent and young adult lymphomas) and develops scientific meetings (including workshops addressing new lymphoma and CLL therapies and clinical trials) annually, convening international experts to share research findings and collaborate, with a goal of advancing the most promising lymphoma and CLL research. LRF funds relevant senior investigator research grants as well, seeking to develop new treatments for lymphoma. To ensure that the next generation of cancer researchers are dedicated to studying lymphoma, the Foundation is committed to investing in early career scientists who have the greatest ability to impact the future of lymphoma research. The Foundation's early career investigator grant portfolio includes the LRF Clinical Career Development Award, Lymphoma Research Clinical Mentoring Program, and LRF Postdoctoral Fellowship, the only lymphoma-specific fellowship program in the United States. Form 990, Part VI, Section A, Line 2 MICHAEL Werner and Robert Werner have a family relationship. Form 990, Part VI, Section B, Line 11b THE ORGANIZATION'S FORM 990 IS PREPARED INTERNALLY BY THE FINANCE DEPARTMENT AND IS REVIEWED BY MANAGEMENT BEFORE REVIEW BY THE ORGANIZATION'S INDEPENDENT ACCOUNTING FIRM. THE FORM 990 IS THEN REVIEWED BY THE AUDIT COMMITTEE AND THE BOARD FOR COMMENT. Form 990, Part VI, Section B, Line 12c LRF has a conflict of interest policy which requires board members, officers, and staff, to review and sign annually. During the FY18 financial audit, LRF's external auditors reviewed the board and officers' statements. No conflict of interests were reported for the fiscal period ending June 30, 2019. In 2014, LRF established a formal process for review and disposition of potential conflicts of interest in accordance with the provisions of the New York Non-Profit Revitalization Act of 2013. FORM 990, PART VI, SECTION B, LINE 15 THE ORGANIZATION SETS COMPENSATION IN A MANNER GIVING RISE TO A REBUTTABLE PRESUMPTION THAT THE COMPENSATION IS REASONABLE UNDER STANDARDS SET FORTH IN TREASURY REGULATIONS SECTION 53.4958-6. SALARIES OF THE SENIOR STAFF, INCLUDING THE CEO, ARE DETERMINED BASED UPON MARKET INFORMATION COMPARABLE TO THE POSITION IN OTHER NON-PROFIT ORGANIZATIONS. THE CEO'S COMPENSATION IS APPROVED BY THE INTEGRATION COUNCIL, WHICH HAS BEEN DULY AUTHORIZED BY THE BOARD AND CONSISTS OF INDEPENDENT MEMBERS, AND THE APPROVAL IS DOCUMENTED CONTEMPORANEOUSLY IN THE COUNCIL MINUTES. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE ON THE ORGANIZATION'S WEBSITE FOR VIEWING. SIGNED CONFLICT OF INTERESTS FORMS AND GOVERNING DOCUMENTS ARE KEPT ON FILE IN LRF'S MAIN OFFICE AND AVAILABLE FOR VIEW ON-SITE. Form 990, Part XI, line 9 During fiscal year 2017, the Foundation established a subsidiary, LRF Research Inc., as part of a strategic relationship with the Clarus Cancer Fund, an investment fund of Clarus Ventures. The subsidiary was closed and expenses for the subsidiary were recaptured in FY2019. LRF Research Inc Wall Street Plaza/88 Pine St Ste New York NY 10005 611844536 Investment NY Lymphoma Resear C 0 0 1.00000 true false false false false false false false false false false false false true true false false false false LRF Research Inc N 25067 invoices paid